Saud H AlDubayan1,2,3,4, Louise C Pyle5,6, Marija Gamulin7, Tomislav Kulis8, Nathanael D Moore2, Amaro Taylor-Weiner2, Anis A Hamid1,2, Brendan Reardon1,2, Bradley Wubbenhorst6, Rama Godse6, David J Vaughn9, Linda A Jacobs10, Stefanie Meien11, Mislav Grgic7, Zeljko Kastelan8, Sarah C Markt12, Scott M Damrauer13, Daniel J Rader14, Rachel L Kember14, Jennifer T Loud15, Peter A Kanetsky16, Mark H Greene15, Christopher J Sweeney1, Christian Kubisch11, Katherine L Nathanson6,10, Eliezer M Van Allen1,2, Douglas R Stewart15, Davor Lessel11. 1. Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. 2. Cancer Program, the Broad Institute of MIT and Harvard, Cambridge, Massachusetts. 3. Division of Genetics, Brigham and Women's Hospital, Boston, Massachusetts. 4. Department of Medicine, King Saud bin Abdul-Aziz University for Health Sciences, Riyadh, Saudi Arabia. 5. Division of Human Genetics, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania. 6. Division of Translational Medicine and Human Genetics, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia. 7. Division of Medical Oncology, Urogenital Unit, Department of Oncology, University Hospital Centre Zagreb, Zagreb, Croatia. 8. Department of Urology, University Hospital Center Zagreb, University of Zagreb, School of Medicine, Zagreb, Croatia. 9. Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia. 10. Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia. 11. Institute of Human Genetics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 12. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts. 13. Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia. 14. Department of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia. 15. Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland. 16. Department of Cancer Epidemiology, Moffitt Cancer Center and Research Institute, Tampa, Florida.
Abstract
IMPORTANCE: Approximately 50% of the risk for the development of testicular germ cell tumors (TGCTs) is estimated to be heritable, but no mendelian TGCT predisposition genes have yet been identified. It is hypothesized that inherited pathogenic DNA repair gene (DRG) alterations may drive susceptibility to TGCTs. OBJECTIVE: To systematically evaluate the enrichment of germline pathogenic variants in the mendelian cancer predisposition DRGs in patients with TGCTs vs healthy controls. DESIGN, SETTING, AND PARTICIPANTS: A case-control enrichment analysis was performed from January 2016 to May 2018 to screen for 48 DRGs in 205 unselected men with TGCT and 27 173 ancestry-matched cancer-free individuals from the Exome Aggregation Consortium cohort in the discovery stage. Significant findings were selectively replicated in independent cohorts of 448 unselected men with TGCTs and 442 population-matched controls, as well as 231 high-risk men with TGCTs and 3090 ancestry-matched controls. Statistical analysis took place from January to May 2018. MAIN OUTCOMES AND MEASURES: Gene-level enrichment analysis of germline pathogenic variants in individuals with TGCTs relative to cancer-free controls. RESULTS: Among 205 unselected men with TGCTs (mean [SD] age, 33.04 [9.67] years), 22 pathogenic germline DRG variants, one-third of which were in CHEK2 (OMIM 604373), were identified in 20 men (9.8%; 95% CI, 6.1%-14.7%). Unselected men with TGCTs were approximately 4 times more likely to carry germline loss-of-function CHEK2 variants compared with cancer-free individuals from the Exome Aggregation Consortium cohort (odds ratio [OR], 3.87; 95% CI, 1.65-8.86; nominal P = .006; q = 0.018). Similar enrichment was also seen in an independent cohort of 448 unselected Croatian men with TGCTs (mean [SD] age, 31.98 [8.11] years) vs 442 unselected Croatian men without TGCTs (at least 50 years of age at time of sample collection) (OR, >1.4; P = .03) and 231 high-risk men with TGCTs (mean [SD] age, 31.54 [9.24] years) vs 3090 men (all older than 50 years) from the Penn Medicine Biobank (OR, 6.30; 95% CI, 2.34-17.31; P = .001). The low-penetrance CHEK2 variant (p.Ile157Thr) was found to be a Croatian founder TGCT risk variant (OR, 3.93; 95% CI, 1.53-9.95; P = .002). Individuals with the pathogenic CHEK2 loss-of-function variants developed TGCTs 6 years earlier than individuals with CHEK2 wild-type alleles (5.95 years; 95% CI, 1.48-10.42; P = .009). CONCLUSIONS AND RELEVANCE: This multicenter case-control analysis of men with or without TGCTs provides evidence for CHEK2 as a novel moderate-penetrance TGCT susceptibility gene, with potential clinical utility. In addition to highlighting DNA-repair deficiency as a potential mechanism driving TGCT susceptibility, this analysis also provides new avenues to explore management strategies and biological investigations for high-risk individuals.
IMPORTANCE: Approximately 50% of the risk for the development of testicular germ cell tumors (TGCTs) is estimated to be heritable, but no mendelian TGCT predisposition genes have yet been identified. It is hypothesized that inherited pathogenic DNA repair gene (DRG) alterations may drive susceptibility to TGCTs. OBJECTIVE: To systematically evaluate the enrichment of germline pathogenic variants in the mendelian cancer predisposition DRGs in patients with TGCTs vs healthy controls. DESIGN, SETTING, AND PARTICIPANTS: A case-control enrichment analysis was performed from January 2016 to May 2018 to screen for 48 DRGs in 205 unselected men with TGCT and 27 173 ancestry-matched cancer-free individuals from the Exome Aggregation Consortium cohort in the discovery stage. Significant findings were selectively replicated in independent cohorts of 448 unselected men with TGCTs and 442 population-matched controls, as well as 231 high-risk men with TGCTs and 3090 ancestry-matched controls. Statistical analysis took place from January to May 2018. MAIN OUTCOMES AND MEASURES: Gene-level enrichment analysis of germline pathogenic variants in individuals with TGCTs relative to cancer-free controls. RESULTS: Among 205 unselected men with TGCTs (mean [SD] age, 33.04 [9.67] years), 22 pathogenic germline DRG variants, one-third of which were in CHEK2 (OMIM 604373), were identified in 20 men (9.8%; 95% CI, 6.1%-14.7%). Unselected men with TGCTs were approximately 4 times more likely to carry germline loss-of-function CHEK2 variants compared with cancer-free individuals from the Exome Aggregation Consortium cohort (odds ratio [OR], 3.87; 95% CI, 1.65-8.86; nominal P = .006; q = 0.018). Similar enrichment was also seen in an independent cohort of 448 unselected Croatian men with TGCTs (mean [SD] age, 31.98 [8.11] years) vs 442 unselected Croatian men without TGCTs (at least 50 years of age at time of sample collection) (OR, >1.4; P = .03) and 231 high-risk men with TGCTs (mean [SD] age, 31.54 [9.24] years) vs 3090 men (all older than 50 years) from the Penn Medicine Biobank (OR, 6.30; 95% CI, 2.34-17.31; P = .001). The low-penetrance CHEK2 variant (p.Ile157Thr) was found to be a Croatian founder TGCT risk variant (OR, 3.93; 95% CI, 1.53-9.95; P = .002). Individuals with the pathogenic CHEK2 loss-of-function variants developed TGCTs 6 years earlier than individuals with CHEK2 wild-type alleles (5.95 years; 95% CI, 1.48-10.42; P = .009). CONCLUSIONS AND RELEVANCE: This multicenter case-control analysis of men with or without TGCTs provides evidence for CHEK2 as a novel moderate-penetrance TGCT susceptibility gene, with potential clinical utility. In addition to highlighting DNA-repair deficiency as a potential mechanism driving TGCT susceptibility, this analysis also provides new avenues to explore management strategies and biological investigations for high-risk individuals.
Authors: Amaro Taylor-Weiner; Travis Zack; Elizabeth O'Donnell; Jennifer L Guerriero; Brandon Bernard; Anita Reddy; G Celine Han; Saud AlDubayan; Ali Amin-Mansour; Steven E Schumacher; Kevin Litchfield; Clare Turnbull; Stacey Gabriel; Rameen Beroukhim; Gad Getz; Scott L Carter; Michelle S Hirsch; Anthony Letai; Christopher Sweeney; Eliezer M Van Allen Journal: Nature Date: 2016-11-30 Impact factor: 49.962
Authors: Heidi L Rehm; Jonathan S Berg; Lisa D Brooks; Carlos D Bustamante; James P Evans; Melissa J Landrum; David H Ledbetter; Donna R Maglott; Christa Lese Martin; Robert L Nussbaum; Sharon E Plon; Erin M Ramos; Stephen T Sherry; Michael S Watson Journal: N Engl J Med Date: 2015-05-27 Impact factor: 91.245
Authors: Kevin Litchfield; Max Levy; Giulia Orlando; Chey Loveday; Philip J Law; Gabriele Migliorini; Amy Holroyd; Peter Broderick; Robert Karlsson; Trine B Haugen; Wenche Kristiansen; Jérémie Nsengimana; Kerry Fenwick; Ioannis Assiotis; ZSofia Kote-Jarai; Alison M Dunning; Kenneth Muir; Julian Peto; Rosalind Eeles; Douglas F Easton; Darshna Dudakia; Nick Orr; Nora Pashayan; D Timothy Bishop; Alison Reid; Robert A Huddart; Janet Shipley; Tom Grotmol; Fredrik Wiklund; Richard S Houlston; Clare Turnbull Journal: Nat Genet Date: 2017-06-12 Impact factor: 38.330
Authors: Kevin Litchfield; Hauke Thomsen; Jonathan S Mitchell; Jan Sundquist; Richard S Houlston; Kari Hemminki; Clare Turnbull Journal: Sci Rep Date: 2015-09-09 Impact factor: 4.379
Authors: Saud H AlDubayan; Jake R Conway; Sabrina Y Camp; Leora Witkowski; Eric Kofman; Brendan Reardon; Seunghun Han; Nicholas Moore; Haitham Elmarakeby; Keyan Salari; Hani Choudhry; Abdullah M Al-Rubaish; Abdulsalam A Al-Sulaiman; Amein K Al-Ali; Amaro Taylor-Weiner; Eliezer M Van Allen Journal: JAMA Date: 2020-11-17 Impact factor: 56.272
Authors: Lauren M Vasta; Mary L McMaster; Laura A Harney; Alexander Ling; Jung Kim; Anne K Harris; Ann G Carr; Scott M Damrauer; Daniel J Rader; Rachel L Kember; Peter A Kanetsky; Katherine L Nathanson; Louise C Pyle; Mark H Greene; Kris Ann Schultz; Douglas R Stewart Journal: Cancer Genet Date: 2020-10-24
Authors: Sabrina Y Camp; Eric Kofman; Brendan Reardon; Nathanael D Moore; Abdullah M Al-Rubaish; Mohammed Aljumaan; Amein K Al-Ali; Eliezer M Van Allen; Amaro Taylor-Weiner; Saud H AlDubayan Journal: Genet Med Date: 2021-02-02 Impact factor: 8.864
Authors: Irene Rainville; Shanell Hatcher; Eric Rosenthal; Katie Larson; Ryan Bernhisel; Stephanie Meek; Heidi Gorringe; Erin Mundt; Susan Manley Journal: Breast Cancer Res Treat Date: 2020-01-28 Impact factor: 4.872
Authors: Andreia Brandão; Paula Paulo; Sofia Maia; Manuela Pinheiro; Ana Peixoto; Marta Cardoso; Maria P Silva; Catarina Santos; Rosalind A Eeles; Zsofia Kote-Jarai; Kenneth Muir; Johanna Schleutker; Ying Wang; Nora Pashayan; Jyotsna Batra; Henrik Grönberg; David E Neal; Børge G Nordestgaard; Catherine M Tangen; Melissa C Southey; Alicja Wolk; Demetrius Albanes; Christopher A Haiman; Ruth C Travis; Janet L Stanford; Lorelei A Mucci; Catharine M L West; Sune F Nielsen; Adam S Kibel; Olivier Cussenot; Sonja I Berndt; Stella Koutros; Karina Dalsgaard Sørensen; Cezary Cybulski; Eli Marie Grindedal; Jong Y Park; Sue A Ingles; Christiane Maier; Robert J Hamilton; Barry S Rosenstein; Ana Vega; Manolis Kogevinas; Fredrik Wiklund; Kathryn L Penney; Hermann Brenner; Esther M John; Radka Kaneva; Christopher J Logothetis; Susan L Neuhausen; Kim De Ruyck; Azad Razack; Lisa F Newcomb; Davor Lessel; Nawaid Usmani; Frank Claessens; Manuela Gago-Dominguez; Paul A Townsend; Monique J Roobol; Manuel R Teixeira Journal: Cancers (Basel) Date: 2020-11-04 Impact factor: 6.639
Authors: John Pluta; Louise C Pyle; Kevin T Nead; Rona Wilf; Mingyao Li; Nandita Mitra; Benita Weathers; Kurt D'Andrea; Kristian Almstrup; Lynn Anson-Cartwright; Javier Benitez; Christopher D Brown; Stephen Chanock; Chu Chen; Victoria K Cortessis; Alberto Ferlin; Carlo Foresta; Marija Gamulin; Jourik A Gietema; Chiara Grasso; Mark H Greene; Tom Grotmol; Robert J Hamilton; Trine B Haugen; Russ Hauser; Michelle A T Hildebrandt; Matthew E Johnson; Robert Karlsson; Lambertus A Kiemeney; Davor Lessel; Ragnhild A Lothe; Jennifer T Loud; Chey Loveday; Paloma Martin-Gimeno; Coby Meijer; Jérémie Nsengimana; David I Quinn; Thorunn Rafnar; Shweta Ramdas; Lorenzo Richiardi; Rolf I Skotheim; Kari Stefansson; Clare Turnbull; David J Vaughn; Fredrik Wiklund; Xifeng Wu; Daphne Yang; Tongzhang Zheng; Andrew D Wells; Struan F A Grant; Ewa Rajpert-De Meyts; Stephen M Schwartz; D Timothy Bishop; Katherine A McGlynn; Peter A Kanetsky; Katherine L Nathanson Journal: Nat Commun Date: 2021-07-23 Impact factor: 14.919